Clinical Trials Directory

Trials / Completed

CompletedNCT01753479

Spectroscopy From Duodenum

Duodenal Spectroscopy Study for Cancer Diagnosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
445 (actual)
Sponsor
Olympus Corporation · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Purpose of this study is to understand the clinical feasibility of duodenal spectroscopy to adenocarcinoma patients.

Detailed description

Pancreatic cancer (PC) is the most lethal of all major cancers with a five year survival rate of 5 %. While stage I and II tumors leads to an improvement in survival, almost all PCs are currently diagnosed at more advanced non-resectable stages since minimally invasive technique which is capable of screening early-stage PC does not exist. Serum CA19-9 is not recommended as a screening technique because of its low sensitivity and specificity. Imaging modalities such as MRI, CT, EUS and ERCP are more accurate but are not appropriate screening tools due to their high cost, discomfort and complications. Therefore, there is a strong demand for a screening tool with high sensitivity and specificity which is highly acceptable for the patient. The investigators would like to look at the spectroscopy technique for pancreatic cancer diagnosis via an upper endoscopy. A definite diagnosis of the patient is made with histology, cytology or imaging diagnosis. Therefore this study can be positioned as a feasibility study.

Conditions

Interventions

TypeNameDescription
OTHERSpectroscopy deviceSpectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.

Timeline

Start date
2013-01-01
Primary completion
2016-06-30
Completion
2016-06-30
First posted
2012-12-20
Last updated
2017-03-07

Locations

4 sites across 3 countries: United States, Belgium, Italy

Source: ClinicalTrials.gov record NCT01753479. Inclusion in this directory is not an endorsement.